Infinity Pharmaceuticals (INFI) and CTI BioPharma Corp. (CTIC) Financial Survey
Infinity Pharmaceuticals (NASDAQ: INFI) and CTI BioPharma Corp. (NASDAQ:CTIC) are both small-cap biotechnology & medical research – nec companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Risk and Volatility
Infinity Pharmaceuticals has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500. Comparatively, CTI BioPharma Corp. has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Institutional and Insider Ownership
67.0% of Infinity Pharmaceuticals shares are held by institutional investors. Comparatively, 43.0% of CTI BioPharma Corp. shares are held by institutional investors. 6.8% of Infinity Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of CTI BioPharma Corp. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Infinity Pharmaceuticals and CTI BioPharma Corp.’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Infinity Pharmaceuticals||$18.72 million||6.53||-$30.10 million||($1.14)||-2.11|
|CTI BioPharma Corp.||$57.40 million||2.21||-$52.00 million||($1.19)||-2.48|
Infinity Pharmaceuticals has higher revenue, but lower earnings than CTI BioPharma Corp.. CTI BioPharma Corp. is trading at a lower price-to-earnings ratio than Infinity Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for Infinity Pharmaceuticals and CTI BioPharma Corp., as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|CTI BioPharma Corp.||0||0||1||0||3.00|
CTI BioPharma Corp. has a consensus target price of $7.50, indicating a potential upside of 154.24%. Given CTI BioPharma Corp.’s higher possible upside, analysts clearly believe CTI BioPharma Corp. is more favorable than Infinity Pharmaceuticals.
This table compares Infinity Pharmaceuticals and CTI BioPharma Corp.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|CTI BioPharma Corp.||-96.91%||-209.67%||-50.35%|
Infinity Pharmaceuticals beats CTI BioPharma Corp. on 7 of the 11 factors compared between the two stocks.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.